Trinity Biotech Files 6-K for 2025 Reporting

TL;DR

Trinity Biotech (TRNB) filed a 6-K, confirming 20-F annual reports. Standard procedure.

AI Summary

Trinity Biotech plc filed a Form 6-K on February 4, 2025, to report its status as a foreign private issuer. The filing confirms that the company will file its annual reports under cover of Form 20-F. The company is incorporated in Ireland and its principal executive offices are located in Bray, Co. Wicklow.

Why It Matters

This filing is a routine procedural document for foreign private issuers, indicating how they will comply with SEC reporting requirements.

Risk Assessment

Risk Level: low — This is a routine administrative filing and does not contain new financial or operational information.

Key Players & Entities

• TRINITY BIOTECH PLC (company) — Registrant
• 0000888721 (company) — Central Index Key
• 2835 (company) — Standard Industrial Classification
• IDA Business Park, Bray, Co. Wicklow, Ireland (company) — Principal Executive Office Address
• 3 ROCK ROAD, SANDYFORD INDUSTRIAL ESTATES, DUBLIN, IRELAND (company) — Mail Address
• February 2025 (date) — Reporting Period
• 20250204 (date) — Filing Date

FAQ

Filing Documents

• zk2532651.htm (6-K) — 16KB
• 0001178913-25-000318.txt ( ) — 17KB

Forward-Looking Statements

Forward-Looking Statements This filing includes statements that constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Reform Act"), including but not limited to statements related to Trinity Biotech's cash position, financial resources and potential for future growth, market acceptance and penetration of new or planned product offerings, and future recurring revenues and results of operations. Trinity Biotech claims the protection of the safe harbor for forward-looking statements contained in the Reform Act. These forward-looking statements are often characterized by the terms "may," "believes," "projects," "expects," "anticipates," or words of similar import, and do not reflect historical facts. Specific forward-looking statements contained in this release may be affected by risks and uncertainties, including, but not limited to, our ability to capitalize on the Waveform transaction and of our recent acquisitions, our continued listing on the Nasdaq Stock Market, our ability to achieve profitable operations in the future, the impact of the spread of COVID-19 and its variants, potential excess inventory levels and inventory imbalances at the company's distributors, losses or system failures with respect to Trinity Biotech's facilities or manufacturing operations, the effect of exchange rate fluctuations on international operations, fluctuations in quarterly operating results, dependence on suppliers, the market acceptance of Trinity Biotech's products and services, the continuing development of its products, required government approvals, continuing international government financial support for healthcare programs, risks associated with manufacturing and distributing its products on a commercial scale free of defects, risks related to the introduction of new instruments manufactured by third parties, risks associated with competing in the human diagnostic market, risks related to the protection of

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. TRINITY BIOTECH PLC Trinity Biotech plc (Registrant) By: /s/ Louise Tallon Louise Tallon Chief Financial Officer Date: February 4, 2025

View Full Filing

View this 6-K filing on SEC EDGAR